MCUJF - Medicure Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Medicure Inc.

2-1250 Waverley Street
Winnipeg, MB R3T 6C6

Full Time Employees

Key Executives

Dr. Albert David Friesen Ph.D.Founder, Chairman, Pres & Chief Exec. OfficerN/AN/A71
Mr. James F. Kinley C.A.CFO & Sec.116.35kN/A40
Mr. Graeme William Merchant B.B.A.VP of Commercial Operations148.8k240.85kN/A
Dr. George Roby Thomas M.Pharm, Ph.D.Director of R&DN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Medicure Inc., a specialty pharmaceutical company, engages in the research, clinical development, and commercialization of human therapeutics in Canada, the United States, Barbados, and India. The company primarily markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction, as well as AGGRASTAT high-dose bolus regimen for the reduction of thrombotic cardiovascular events in patients with non-ST elevated acute coronary syndrome. It is also developing TARDOXAL that is in Phase IIa clinical trials for the treatment of tardive dyskinesia/neurological indications. In addition, the company manufactures, develops, markets, and sells active pharmaceutical ingredients to generic pharmaceutical customers; and provides customs synthesis for early phase pharmaceutical research of branded products, as well as participates in collaborations with other parties in the research and development stages of specific products. Medicure Inc. was founded in 1997 and is headquartered in Winnipeg, Canada.

Corporate Governance

Medicure Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.